Skip to content

Author

Svetomir N. Markovic

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework

Abstract Enfortumab vedotin (EV), pembrolizumab, and EV plus pembrolizumab (EV/P) have rapidly reshaped the treatment landscape of advanced urothelial carcinoma, but toxicity increasingly determines treatment delivery, treatment continuity, and real-world benefit. As EV/P moves into broader clinical use, clinicians mus...

Jabra G. Zarka, D. Childs, Miguel Muniz Rincon et al. · 0 citations
Review Open access Sep 2026

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact

This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.

Joud Hajjar, B. Stephen, A. Aaroe et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.